Market News

Pacira Pharmaceuticals (PCRX) Got Lower Mizuho Securities Rating And $44.0 Target; Strs Ohio Has Lifted Crown Holdings (CCK) Holding By $5.21 Million

Strs Ohio increased Crown Holdings Inc (CCK) stake by 4655.19% reported in 2017Q2 SEC filing. Strs Ohio acquired 88,309 shares as Crown Holdings Inc (CCK)’s stock rose 6.12%. The Strs Ohio holds 90,206 shares with $5.38M value, up from 1,897 last quarter. Crown Holdings Inc now has $7.97 billion valuation. The stock increased 0.17% or $0.1 during the last trading session, reaching $59.32. About 38,691 shares traded. Crown Holdings, Inc. (NYSE:CCK) has risen 7.50% since November 30, 2016 and is uptrending. It has underperformed by 9.20% the S&P500.

Among 19 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 8 Hold. Therefore 53% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $56.44’s average target is 22.96% above currents $45.9 stock price. Pacira Pharmaceuticals had 73 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Thursday, August 3 by BMO Capital Markets. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Neutral” rating by Mizuho on Wednesday, November 29. As per Monday, August 21, the company rating was upgraded by Janney Capital. Wedbush maintained the stock with “Buy” rating in Monday, August 7 report. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Hold” rating given on Friday, July 14 by Cowen & Co. The company was maintained on Wednesday, August 2 by Piper Jaffray. On Wednesday, June 29 the stock rating was initiated by BMO Capital Markets with “Underperform”. The company was initiated on Tuesday, September 29 by Nomura. The stock has “Buy” rating by Bank of America on Wednesday, October 4. The firm has “Buy” rating by Wedbush given on Tuesday, July 25.

Among 15 analysts covering Crown Holdings (NYSE:CCK), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Crown Holdings had 41 analyst reports since July 22, 2015 according to SRatingsIntel. On Friday, September 1 the stock rating was maintained by BMO Capital Markets with “Buy”. Macquarie Research maintained Crown Holdings, Inc. (NYSE:CCK) rating on Friday, February 5. Macquarie Research has “Outperform” rating and $58 target. The firm earned “Buy” rating on Tuesday, August 22 by RBC Capital Markets. The rating was maintained by Barclays Capital with “Overweight” on Friday, October 20. The stock has “Buy” rating by Robert W. Baird on Tuesday, October 10. The firm has “Buy” rating given on Monday, September 25 by RBC Capital Markets. The firm has “Buy” rating given on Friday, June 23 by BMO Capital Markets. The firm has “Market Perform” rating by Wells Fargo given on Thursday, November 12. The firm has “Market Perform” rating by Wells Fargo given on Friday, October 20. TheStreet upgraded the shares of CCK in report on Wednesday, July 22 to “Buy” rating.

Investors sentiment decreased to 0.85 in 2017 Q2. Its down 0.17, from 1.02 in 2017Q1. It fall, as 36 investors sold CCK shares while 106 reduced holdings. 33 funds opened positions while 87 raised stakes. 120.15 million shares or 2.54% less from 123.29 million shares in 2017Q1 were reported. Fayez Sarofim And Company reported 8,100 shares. Envestnet Asset Mgmt Inc accumulated 0.01% or 50,055 shares. Hl Financial Ltd Limited Liability Company has invested 0.01% in Crown Holdings, Inc. (NYSE:CCK). Asset Mngmt One Limited holds 0.03% or 208,798 shares. Madison Invest accumulated 0.71% or 645,279 shares. Victory Capital Incorporated has invested 0.56% in Crown Holdings, Inc. (NYSE:CCK). Valley Natl Advisers stated it has 225 shares. Glg holds 0.02% or 6,460 shares in its portfolio. Goldman Sachs Grp Inc reported 653,305 shares stake. Amer Century Companies Inc reported 0% of its portfolio in Crown Holdings, Inc. (NYSE:CCK). Gabelli Funds Limited Liability Company has 0.1% invested in Crown Holdings, Inc. (NYSE:CCK). State Of Wisconsin Investment Board reported 0.06% stake. Fjarde Ap, Alabama-based fund reported 45,160 shares. Brandywine Global holds 1.62 million shares. Voya Mngmt Limited Liability Company has invested 0.47% of its portfolio in Crown Holdings, Inc. (NYSE:CCK).

Strs Ohio decreased Ingevity Corp stake by 15,700 shares to 60,900 valued at $3.50M in 2017Q2. It also reduced Abiomed Inc (NASDAQ:ABMD) stake by 36,000 shares and now owns 34,867 shares. Prestige Brands Holdings Inc (NYSE:PBH) was reduced too.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on March, 7. They expect $-0.15 earnings per share, down 25.00% or $0.03 from last year’s $-0.12 per share. After $-0.11 actual earnings per share reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 36.36% negative EPS growth.

Investors sentiment increased to 1.62 in 2017 Q2. Its up 0.45, from 1.17 in 2017Q1. It increased, as 23 investors sold Pacira Pharmaceuticals, Inc. shares while 45 reduced holdings. 37 funds opened positions while 73 raised stakes. 39.35 million shares or 1.09% less from 39.78 million shares in 2017Q1 were reported. Ameritas Investment Prns accumulated 3,449 shares. Waddell Reed Inc owns 815,566 shares or 0.09% of their US portfolio. The Connecticut-based Great Point Prtnrs Limited Liability has invested 2.56% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Great West Life Assurance Can stated it has 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Manufacturers Life Ins The owns 30,307 shares. Tiaa Cref Inv Ltd holds 0.01% or 191,224 shares. Amer Century invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Elk Creek Ptnrs Limited Liability Co holds 1.71% or 552,656 shares in its portfolio. 6,064 were reported by Jane Street Group Limited Com. Granahan Investment Inc Ma holds 140,855 shares or 0.62% of its portfolio. Citigroup reported 96,781 shares. Sandell Asset Mngmt reported 47,600 shares stake. Mutual Of America Cap Mgmt Limited Liability Company invested 0.05% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Denver Investment Advsrs Lc stated it has 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Geode Capital Mngmt stated it has 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

The stock decreased 0.43% or $0.2 during the last trading session, reaching $45.9. About 61,249 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 12.40% since November 30, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Since June 5, 2017, it had 0 insider purchases, and 7 selling transactions for $495,424 activity. On Wednesday, June 7 Riker Lauren Bullaro sold $49,650 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 1,119 shares. $33,271 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by Braunstein Scott. 1,877 shares were sold by Williams Kristen Marie, worth $81,314. Shares for $85,169 were sold by Scibetta James S on Monday, June 5. On Monday, June 5 Jones James B sold $33,227 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 767 shares. Another trade for 4,311 shares valued at $186,757 was made by STACK DAVID M on Monday, June 5.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.86 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *